Sanofi, revenues and profits up in Q1

Positive start to the year for Sanofi, which closed 1Q2026 with double-digit growth at constant exchange rates in key operating indicators, supported by the contribution of new launches and the performance of flagship drugs. Revenues stood at €10.5 billion, up 13.6% at constant exchange rates (+6.2% at actual exchange rates), while operating earnings per share reached €1.88, up 14%.

'We had a solid start to the year, with double-digit growth in both sales and operating EPS,' commented interim CEO Olivier Charmeil, emphasising the contribution of new products and recent acquisitions.

Driving the accounts is once again Dupixent, which again exceeds the EUR 4 billion mark on a quarterly basis, with sales of EUR 4.2 billion (+30.8%). The contribution of new launches in the pharmaceuticals segment was also decisive, increasing by 49.6% to EUR 1.2 billion. In the vaccines segment, revenues rose to EUR 1.3 billion (+2.1%), benefiting in particular from the integration of Heplisav-B.

On the square in Paris, the stock had gained more than 3.5% during the day, only to fall back and close 0.93% higher.

On the profitability front, operating profit stood at EUR 2.97 billion, up 10.9% at constant exchange rates, with a margin of 28.6%, slightly down from the previous year. The result was mainly affected by higher operating expenses, particularly 'other expenses' (+62.4%), largely related to higher profit sharing with Regeneron, as well as higher sales and general expenses (+11.6%) related to recent acquisitions. Research and development expenses, on the other hand, remained under control, up a moderate 1.5% to EUR 1.7 billion, according to the French group. Net profit stood at EUR 1.61 billion, down 13.8%, while EPS fell to EUR 1.34 (-11.8%).